Abivax Shares Continue to Soar Mid-Day: +4.59% at 127.60 Euros
The French biotech company Abivax recorded a 4.59% increase this Monday, December 29th, at mid-day, bringing its share price to 127.60 euros from 122.00 euros the previous day. This new rise occurs amidst ongoing speculation about a potential acquisition by pharmaceutical giant Eli Lilly, while the stock, eligible for the PEA-PME, continues to attract attention with a staggering annual performance of 1,710%. With only 0.08% of the capital traded, volumes remain contained at the end of the year.
Market Capitalization and Recent Performance
The stock now displays a market capitalization of approximately 11 billion dollars, surpassing some of the CAC 40 values. Over the past week, Abivax's shares have climbed 27.6%, confirming the upward momentum that began in mid-December. The quarterly performance reached 81.51%, driven by positive clinical announcements last July and the recent inclusion in the Nasdaq Biotechnology Index. Today's movement extends a series of consecutive rises, with a monthly volatility of 25.39% indicating the intensity of the fluctuations. Despite this marked progress, trading remains limited at mid-day, reflecting typical end-of-year caution in biotech stocks. The current price of 127.60 euros now exceeds the previously set resistance threshold of 122.00 euros, potentially paving the way for new highs. The identified support at 89.40 euros serves as a reference point in case of a reversal, although there is no indication of this at the moment. The 50-day moving average is established at 96.07 euros, confirming the solidity of the medium-term upward trend. The gap with the 200-day moving average, positioned at 47.43 euros, illustrates the magnitude of the stock's revaluation since the beginning of the year, as the biotech has multiplied its course by more than 18.
Potential Acquisition by Eli Lilly and Market Prospects
According to the media outlet La Lettre, a delegation from Eli Lilly visited the French Treasury Directorate on December 10 for a preliminary 'test' regarding an acquisition. The Treasury has stated it is 'closely monitoring' the Abivax file, noting that checks are underway. These statements fuel speculation about a potential takeover of the French biotech by the American pharmaceutical giant, although no official confirmation has been provided. Abivax estimates that the market for treatments for chronic inflammatory bowel diseases could be worth 30 billion dollars by 2030. Additionally, Abivax's inclusion in the Nasdaq Biotechnology Index on December 22nd last year enhances its visibility among international institutional investors. This inclusion reflects recognition of the commercial potential of obezafimod, its leading drug candidate against ulcerative colitis. The positive results of the eight-week phase 3 trials announced in July 2025 marked a key milestone, with maintenance data expected in the second quarter of 2026. Several analysts have raised their price targets in recent weeks, with Truist Securities aiming for 140 euros and Wolfe Research setting an ambitious target at 176 euros.
Technical Indicators and Financial Stability
The RSI shows a level of 70 at mid-day, signaling a technical overbought zone that calls for short-term caution. This threshold indicates that the stock might undergo a consolidation phase after its recent progression. The MACD histogram remains positive at 1.44, with a MACD line at 4.10 above its signal line at 2.66, confirming that the bullish momentum remains intact in the short term. This setup suggests that buyers maintain control, although the high RSI limits immediate progression potential. The Bollinger Bands frame the stock between 87.46 euros and 122.87 euros, with the current price of 127.60 euros slightly above the upper boundary. This position reflects an extension of the bullish movement beyond usual statistical limits, reinforcing the idea of a possible technical pause ahead. The very low beta of 0.02 confirms the stock's almost total decorrelation with the CAC 40, allowing Abivax to evolve according to its own dynamics, independent of the fluctuations of the Paris market. With a treasury of 589.7 million euros as of September 30, 2025, the company has financial autonomy until the fourth quarter of 2027, reassuring investors about its ability to continue its clinical programs.
